Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
A recently proposed therapeutic approach for lysosomal storage disorders (LSDs) relies upon the ability of transcription factor EB (TFEB) to stimulate autophagy and induce lysosomal exocytosis leading to cellular clearance. This approach is particularly attractive in glycogen storage disease type II [a severe metabolic myopathy, Pompe disease (PD)] as the currently available therapy, replacement of the missing enzyme acid alpha-glucosidase, fails to reverse skeletal muscle pathology. PD, a paradigm for LSDs, is characterized by both lysosomal abnormality and dysfunctional autophagy. Here, we show that TFEB is a viable therapeutic target in PD: overexpression of TFEB in a new muscle cell culture system and in mouse models of the disease reduced glycogen load and lysosomal size, improved autophagosome processing, and alleviated excessive accumulation of autophagic vacuoles. Unexpectedly, the exocytosed vesicles were labelled with lysosomal and autophagosomal membrane markers, suggesting that TFEB induces exocytosis of autophagolysosomes. Furthermore, the effects of TFEB were almost abrogated in the setting of genetically suppressed autophagy, supporting the role of autophagy in TFEB-mediated cellular clearance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“strategies based on the enhancement of cellular waste disposal capacity (i.e., TFEB‐TFE3 gene therapy) hold promise of preclinical benefits in these pathological scenarios (Spampanato et al, 2013; Bajaj et al, 2019).”
From Autophagy in major human diseases (2021) · cites this paper as Spampanato et al, 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing.
Kabeya, Y., Mizushima, N., Ueno, T., Yamamoto, A., Kirisako, T., Noda, T., Kominami, E., Ohsumi, Y., & Yoshimori, T. (2000) · The EMBO Journal · doi:10.1093/emboj/19.21.5720 · Cited by 6,605 · cited 2×
“…abnormality in PD muscle fibres – autophagic accumulation (Raben et al, 2012) – was not reproduced in PD myotubes, as demonstrated by immunostaining and western analysis with LC3 [a highly specific autophagosomal marker (Kabeya et al, 2000)] (shown for western blot in Supporting Information Fig S1C).”
Cui, C., Cui, J., Jin, F., Cui, Y., Li, R., Jiang, X., Tian, Y., Wang, K., Jiang, P., & Gao, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479571 · Cited by 5,203
TFEB Links Autophagy to Lysosomal Biogenesis
Settembre, C., Di Malta, C., Polito, V. A., Arencibia, M. G., Vetrini, F., Erdin, S., Erdin, S. U., Huynh, T., Medina, D., Colella, P., et al. (2011) · Science · doi:10.1126/science.1204592 · Cited by 3,365 · cited 5×
“Furthermore, since TFEB has been shown to promote lysosomal– autophagosomal fusion (Settembre & Ballabio, 2011; Settembre et al, 2011), this approach, unlike most current efforts, has the potential to prevent or resolve autophagic build-up.”
InfluentialSelf-citationA Gene Network Regulating Lysosomal Biogenesis and Function
Sardiello, M., Palmieri, M., di Ronza, A., Medina, D. L., Valenza, M., Gennarino, V. A., Di Malta, C., Donaudy, F., Embrione, V., Polishchuk, R. S., et al. (2009) · Science · doi:10.1126/science.1174447 · Cited by 2,543 · cited 5×
“Plasmids: plasmid containing the full-length 3xFlag-tagged human TFEB (referred to as Flag-TFEB) was described previously (Sardiello et al, 2009); plasmid containing the full-length rat LAMP1 (mCherry-LAMP1) was obtained from Dr. Kristien Zaal (Light Imaging Section, Office of Science & Technology,…”
InfluentialSelf-citationMammalian autophagy: core molecular machinery and signaling regulation
Yang, Z., & Klionsky, D. J. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.11.014 · Cited by 1,956 · cited 1×
“Defects in autophagy, a major lysosome-dependent degradative system (Yang & Klionsky, 2010)], significantly contribute to the pathophysiology of several lysosomal storage diseases (Cao et al, 2006; Cox & Cachon-Gonzalez, 2012; Fukuda et al, 2006a,b; Liao et al, 2007; Lieberman et al, 2012; Settembre…”
A lysosome‐to‐nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB
Settembre, C., Zoncu, R., Medina, D. L., Vetrini, F., Erdin, S., Erdin, S., Huynh, T., Ferron, M., Karsenty, G., Vellard, M. C., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.32 · Cited by 1,920
Self-citationLysosomes: fusion and function
Luzio, J. P., Pryor, P. R., & Bright, N. A. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2217 · Cited by 1,740 · cited 1×
“Lysosomal function depends on the ability of lysosomal membranes to fuse with other vesicles’ membranes and with the plasma membrane (Luzio et al, 2007).”
Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function
Saftig, P., & Klumperman, J. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2745 · Cited by 1,648 · cited 1×
“LAMPs are considered to be of key importance for lysosomal movement, maturation of autophago-somes and lysosomal exocytosis (Saftig & Klumperman, 2009).”
Roczniak-Ferguson, A., Petit, C. S., Froehlich, F., Qian, S., Ky, J., Angarola, B., Walther, T. C., & Ferguson, S. M. (2012) · Science Signaling · doi:10.1126/scisignal.2002790 · Cited by 1,366
MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB
Martina, J. A., Chen, Y., Gucek, M., & Puertollano, R. (2012) · Autophagy · doi:10.4161/auto.19653 · Cited by 1,333 · cited 6×
“Next, we attempted to activate endogenous TFEB by pharmacologically targeting mTORC1, which has been shown to negatively regulate TFEB (Martina et al, 2012; RoczniakFerguson et al, 2012; Settembre et al, 2012).”
BackgroundMethodInfluentialSelf-citationRecombinant human acid α-glucosidase: Major clinical benefits in infantile-onset Pompe disease
Kishnani, P. S., Corzo, D., Nicolino, M., Byrne, B., Mandel, H., Hwu, W. L., Leslie, N., Levine, J., Spencer, C., McDonald, M., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000251268.41188.04 · Cited by 781 · cited 1×
“…Myozyme1 and Lumizyme1, Genzyme Corporation, Framingham, MA), many patients experience limited clinical benefit or show signs of disease progression (Angelini & Semplicini, 2012; Kishnani et al, 2007; Schoser et al, 2008; Strothotte et al, 2010; Van den Hout et al, 2004; Van der Ploeg et al, 2010).”
Backgroundvan der Ploeg, A. T., & Reuser, A. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61555-x · Cited by 756
A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease
van der Ploeg, A. T., Clemens, P. R., Corzo, D., Escolar, D. M., Florence, J., Groeneveld, G. J., Herson, S., Kishnani, P. S., Laforet, P., Lake, S. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909859 · Cited by 745 · cited 1×
“…Myozyme1 and Lumizyme1, Genzyme Corporation, Framingham, MA), many patients experience limited clinical benefit or show signs of disease progression (Angelini & Semplicini, 2012; Kishnani et al, 2007; Schoser et al, 2008; Strothotte et al, 2010; Van den Hout et al, 2004; Van der Ploeg et al, 2010).”
BackgroundDirect derivation of conditionally immortal cell lines from an H-2Kb-tsA58 transgenic mouse.
Jat, P. S., Noble, M. D., Ataliotis, P., Tanaka, Y., Yannoutsos, N., Larsen, L., & Kioussis, D. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.12.5096 · Cited by 744 · cited 3×
“The cells were then incubated at 338C in an atmosphere of 5% CO2 (Jat et al, 1991).”
MethodInfluentialTranscriptional Activation of Lysosomal Exocytosis Promotes Cellular Clearance
Medina, D. L., Fraldi, A., Bouche, V., Annunziata, F., Mansueto, G., Spampanato, C., Puri, C., Pignata, A., Martina, J. A., Sardiello, M., et al. (2011) · Developmental Cell · doi:10.1016/j.devcel.2011.07.016 · Cited by 716 · cited 7×
“The effect of TFEB was also demonstrated in fibroblasts from a PD patient (Medina et al, 2011), but it remained unclear whether TFEB would have similar effects in terminally differentiated multinucleated muscle cells and PD muscle, the tissue that presents the greatest challenge for ERT.”
InfluentialSelf-citationBlott, E. J., & Griffiths, G. M. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm732 · Cited by 672
A block of autophagy in lysosomal storage disorders
Settembre, C., Fraldi, A., Jahreiss, L., Spampanato, C., Venturi, C., Medina, D., de Pablo, R., Tacchetti, C., Rubinsztein, D. C., & Ballabio, A. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddm289 · Cited by 506 · cited 1×
“…a major lysosome-dependent degradative system (Yang & Klionsky, 2010)], significantly contribute to the pathophysiology of several lysosomal storage diseases (Cao et al, 2006; Cox & Cachon-Gonzalez, 2012; Fukuda et al, 2006a,b; Liao et al, 2007; Lieberman et al, 2012; Settembre et al, 2008).”
Self-citationCulturing satellite cells from living single muscle fiber explants
Rosenblatt, J. D., Lunt, A. I., Parry, D. J., & Partridge, T. A. (1995) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/bf02634119 · Cited by 479 · cited 1×
“Single live myofibres from gastrocnemius and extensor digitorum longus (EDL) muscles from 3 to 4 month-old mice were isolated as described (Rosenblatt et al, 1995).”
Autophagy in lysosomal storage disorders
Lieberman, A. P., Puertollano, R., Raben, N., Slaugenhaupt, S., Walkley, S. U., & Ballabio, A. (2012) · Autophagy · doi:10.4161/auto.19469 · Cited by 399 · cited 1×
“…a major lysosome-dependent degradative system (Yang & Klionsky, 2010)], significantly contribute to the pathophysiology of several lysosomal storage diseases (Cao et al, 2006; Cox & Cachon-Gonzalez, 2012; Fukuda et al, 2006a,b; Liao et al, 2007; Lieberman et al, 2012; Settembre et al, 2008).”
Self-citationCross-reactive immunologic material status affects treatment outcomes in Pompe disease infants
Kishnani, P. S., Goldenberg, P. C., DeArmey, S. L., Heller, J., Benjamin, D., Young, S., Bali, D., Smith, S. A., Li, J. S., Mandel, H., et al. (2010) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2009.08.003 · Cited by 383 · cited 1×
“…response to the recombinant enzyme in cross-reactive immunologic material (CRIM)-negative patients and the presence of large areas of autophagic build-up alongside expanded lysosomes (Banugaria et al, 2011; Funk et al, 1992; Kishnani et al, 2010; Koeberl et al, 2012; Raben et al, 2002, 2010, 2012).”
Long-Term Intravenous Treatment of Pompe Disease With Recombinant Human α-Glucosidase From Milk
Van den Hout, J. M. P., Kamphoven, J. H. J., Winkel, L. P. F., Arts, W. F. M., Klerk, J. B. C. D., Loonen, M. C. B., Vulto, A. G., Cromme-Dijkhuis, A., Weisglas-Kuperus, N., Hop, W., et al. (2004) · Pediatrics · doi:10.1542/peds.113.5.e448 · Cited by 355
Regulated secretion of conventional lysosomes
Andrews, N. W. (2000) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)01794-3 · Cited by 353 · cited 2×
“membrane, followed by fusion with the membrane and a discharge of lysosomal content (Andrews, 2000).”
Identification of SNAREs Involved in Synaptotagmin VII-regulated Lysosomal Exocytosis
Rao, S. K., Huynh, C., Proux-Gillardeaux, V., Galli, T., & Andrews, N. W. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400798200 · Cited by 320 · cited 1×
“This synapto-tagmin-regulated Ca 2 þ -dependent process is considered to be critical for the repair of plasma membrane lesions (Rao et al, 2004).”
H‐2Kb‐tsA58トランスジェニックマウスから直接に無限増殖細胞系を得る方法
Jat, P., Noble, M., Ataliotis, P., Tanaka, Y., Yannoutsos, N., Larsen, L., & Kioussis, D. (1991) · Cited by 310
Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease
Fukuda, T., Ewan, L., Bauer, M., Mattaliano, R. J., Zaal, K., Ralston, E., Plotz, P. H., & Raben, N. (2006) · Annals of Neurology · doi:10.1002/ana.20807 · Cited by 303
Self-citationRaben, N., Nagaraju, K., Lee, E., Kessler, P., Byrne, B., Lee, L., LaMarca, M., King, C., Ward, J., Sauer, B., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.30.19086 · Cited by 299 · cited 1×
“…exocytosis To evaluate the effect of TFEB on lysosomal and autophagic pathologies in vivo, three knockout mouse strains were used: the previously described GAA / and autophagy-deficient GAA / (Atg7:GAA DKO) models (Raben et al, 1998, 2010), and a newly developed GFP-LC3:GAA / strain.”
MethodSelf-citationLiu, Q., Chang, J. W., Wang, J., Kang, S. A., Thoreen, C. C., Markhard, A., Hur, W., Zhang, J., Sim, T., Sabatini, D. M., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101144f · Cited by 257 · cited 2×
“Here, we have characterized the effect of TFEB overexpression on lysosomal and autophagic accumulation in previously described and newly developed PD models.”
Autophagy Is Disrupted in a Knock-in Mouse Model of Juvenile Neuronal Ceroid Lipofuscinosis
Cao, Y., Espinola, J. A., Fossale, E., Massey, A. C., Cuervo, A. M., MacDonald, M. E., & Cotman, S. L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602180200 · Cited by 256 · cited 1×
“…a major lysosome-dependent degradative system (Yang & Klionsky, 2010)], significantly contribute to the pathophysiology of several lysosomal storage diseases (Cao et al, 2006; Cox & Cachon-Gonzalez, 2012; Fukuda et al, 2006a,b; Liao et al, 2007; Lieberman et al, 2012; Settembre et al, 2008).”
Strothotte, S., Strigl-Pill, N., Grunert, B., Kornblum, C., Eger, K., Wessig, C., Deschauer, M., Breunig, F., Glocker, F. X., Vielhaber, S., et al. (2010) · Journal of Neurology · doi:10.1007/s00415-009-5275-3 · Cited by 256 · cited 1×
“…1 and Lumizyme 1 , Genzyme Corporation, Framingham, MA), many patients experience limited clinical benefit or show signs of disease progression (Angelini & Semplicini, 2012; Kishnani et al, 2007; Schoser et al, 2008; Strothotte et al, 2010; Van den Hout et al, 2004; Van der Ploeg et al, 2010).”
Banugaria, S. G., Prater, S. N., Ng, Y.-K., Kobori, J. A., Finkel, R. S., Ladda, R. L., Chen, Y.-T., Rosenberg, A. S., & Kishnani, P. S. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e3182174703 · Cited by 255 · cited 1×
“…response to the recombinant enzyme in cross-reactive immunologic material (CRIM)-negative patients and the presence of large areas of autophagic build-up alongside expanded lysosomes (Banugaria et al, 2011; Funk et al, 1992; Kishnani et al, 2010; Koeberl et al, 2012; Raben et al, 2002, 2010, 2012).”
TFEB regulates autophagy: An integrated coordination of cellular degradation and recycling processes
Settembre, C., & Ballabio, A. (2011) · Autophagy · doi:10.4161/auto.7.11.17166 · Cited by 251
Self-citationFraldi, A., Annunziata, F., Lombardi, A., Kaiser, H., Medina, D. L., Spampanato, C., Fedele, A. O., Polishchuk, R., Sorrentino, N. C., Simons, K., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.237 · Cited by 225
Self-citationThe cellular pathology of lysosomal diseases
Cox, T. M., & Cachón‐González, M. B. (2012) · The Journal of Pathology · doi:10.1002/path.3021 · Cited by 221 · cited 2×
“…a major lysosome-dependent degradative system (Yang & Klionsky, 2010)], significantly contribute to the pathophysiology of several lysosomal storage diseases (Cao et al, 2006; Cox & Cachon-Gonzalez, 2012; Fukuda et al, 2006a,b; Liao et al, 2007; Lieberman et al, 2012; Settembre et al, 2008).”
Martiniuk, F., Chen, A., Mack, A., Arvanitopoulos, E., Chen, Y., Rom, W. N., Codd, W. J., Hanna, B., Alcabes, P., Raben, N., et al. (1998) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19980827)79:1<69::aid-ajmg16>3.0.co;2-k · Cited by 220 · cited 1×
“Although PD is a rare disorder (Martiniuk et al, 1998), it shares common pathological features with many other lysosomal storage disorders (LSDs), which encompass more than 60 nosological entities (Cox & Cachon-Gonzalez, 2012).”
Liao, G., Yao, Y., Liu, J., Yu, Z., Cheung, S., Xie, A., Liang, X., & Bi, X. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070052 · Cited by 220 · cited 1×
“…a major lysosome-dependent degradative system (Yang & Klionsky, 2010)], significantly contribute to the pathophysiology of several lysosomal storage diseases (Cao et al, 2006; Cox & Cachon-Gonzalez, 2012; Fukuda et al, 2006a,b; Liao et al, 2007; Lieberman et al, 2012; Settembre et al, 2008).”
BackgroundAutophagy and Mistargeting of Therapeutic Enzyme in Skeletal Muscle in Pompe Disease
Fukuda, T., Ahearn, M., Roberts, A., Mattaliano, R. J., Zaal, K., Ralston, E., Plotz, P. H., & Raben, N. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.08.009 · Cited by 190 · cited 1×
“…a major lysosome-dependent degradative system (Yang & Klionsky, 2010)], significantly contribute to the pathophysiology of several lysosomal storage diseases (Cao et al, 2006; Cox & Cachon-Gonzalez, 2012; Fukuda et al, 2006a,b; Liao et al, 2007; Lieberman et al, 2012; Settembre et al, 2008).”
Self-citationNeuraminidase 1 Is a Negative Regulator of Lysosomal Exocytosis
Yogalingam, G., Bonten, E. J., van de Vlekkert, D., Hu, H., Moshiach, S., Connell, S. A., & d'Azzo, A. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.05.005 · Cited by 185 · cited 1×
“Interestingly, lysosomal exocytosis has been implicated as a mechanism of cellular clearance in cell models of several LSDs, such as metachromatic leukodystrophy and mucolipidosis type I (Klein et al, 2005; Yogalingam et al, 2008).”
Zhu, Y., Jiang, J.-L., Gumlaw, N. K., Zhang, J., Bercury, S. D., Ziegler, R. J., Lee, K., Kudo, M., Canfield, W. M., Edmunds, T., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.37 · Cited by 177 · cited 1×
“…therapy, such as the development of ‘‘second generation’’ recombinant enzymes with enhanced targeting properties (Maga et al, 2012; Tiels et al, 2012; Zhu et al, 2009), pharmacological chaperones that assist the folding of the mutant enzyme (Okumiya et al, 2007; Parenti et al, 2007) or increase…”
BackgroundRaben, N., Schreiner, C., Baum, R., Takikita, S., Xu, S., Xie, T., Myerowitz, R., Komatsu, M., Van Der Meulen, J. H., Nagaraju, K., et al. (2010) · Autophagy · doi:10.4161/auto.6.8.13378 · Cited by 164
Self-citationPorto, C., Cardone, M., Fontana, F., Rossi, B., Tuzzi, M. R., Tarallo, A., Barone, M. V., Andria, G., & Parenti, G. (2009) · Molecular Therapy · doi:10.1038/mt.2009.53 · Cited by 152 · cited 1×
“…properties (Maga et al, 2012; Tiels et al, 2012; Zhu et al, 2009), pharmacological chaperones that assist the folding of the mutant enzyme (Okumiya et al, 2007; Parenti et al, 2007) or increase the stability of the recombinant enzyme (Porto et al, 2009, 2012), and gene therapy (Byrne et al, 2011).”
BackgroundSelf-citationEnzyme replacement therapy for lysosomal storage diseases
Lachmann, R. H. (2011) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32834c20d9 · Cited by 142
Huang, H.-P., Chen, P.-H., Hwu, W.-L., Chuang, C.-Y., Chien, Y.-H., Stone, L., Chien, C.-L., Li, L.-T., Chiang, S.-C., Chen, H.-F., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr424 · Cited by 138 · cited 1×
“…have been made to develop such a model: these include the generation of cardiomyocyte-like cells from human induced pluripotent stem (iPS) cells (Huang et al, 2011), muscle cells from reprogrammed murine iPS cells (Kawagoe et al, 2011), and murine muscle cells transduced by viral constructs…”
Self-citationThe genotype–phenotype correlation in Pompe disease
Kroos, M., Hoogeveen‐Westerveld, M., van der Ploeg, A., & Reuser, A. J. J. (2012) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.31318 · Cited by 135 · cited 1×
“The functional deficiency or complete absence of the enzyme results in accumulation of glycogen within this cellular compartment (Kroos et al, 2012; Van der Ploeg & Reuser, 2008).”
Xu, M., Liu, K., Swaroop, M., Porter, F. D., Sidhu, R., Finkes, S., Ory, D. S., Marugan, J. J., Xiao, J., Southall, N., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.357707 · Cited by 124 · cited 1×
“Similarly, d-tocopherol was shown to improve the phenotypes in several LSD cell models by stimulating Ca2þ-mediated lysosomal exocytosis (Xu et al, 2012).”
BackgroundParenti, G., Zuppaldi, A., Gabriela Pittis, M., Rosaria Tuzzi, M., Annunziata, I., Meroni, G., Porto, C., Donaudy, F., Rossi, B., Rossi, M., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300074 · Cited by 120 · cited 1×
“…properties (Maga et al, 2012; Tiels et al, 2012; Zhu et al, 2009), pharmacological chaperones that assist the folding of the mutant enzyme (Okumiya et al, 2007; Parenti et al, 2007) or increase the stability of the recombinant enzyme (Porto et al, 2009, 2012), and gene therapy (Byrne et al, 2011).”
BackgroundSelf-citationCyclodextrin Induces Calcium-Dependent Lysosomal Exocytosis
Chen, F. W., Li, C., & Ioannou, Y. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015054 · Cited by 115 · cited 1×
“Furthermore, it has been shown that lysosomal exocytosis is the mechanism by which 2-hydroxypropyl-b -cyclodextrin – an approved drug for yet another LSD, Niemann Pick Type C (NPC) disease – alleviates cholesterol storage in NPC cells (Chen et al, 2010).”
Autophagy and mitochondria in Pompe disease: Nothing is so new as what has long been forgotten
Raben, N., Wong, A., Ralston, E., & Myerowitz, R. (2012) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.31317 · Cited by 112
Self-citationDeconstructing Pompe Disease by Analyzing Single Muscle Fibers: “To See a World in a Grain of Sand…”
Raben, N., Takikita, S., Pittis, M. G., Bembi, B., Marie, S. K. N., Roberts, A., Page, L., Kishnani, P. S., Schoser, B. G. H., Chien, Y.-H., et al. (2007) · Autophagy · doi:10.4161/auto.4591 · Cited by 112 · cited 2×
“The development of a new PD mouse model, the GFPLC3:GAA / strain, allowed us to address the effect of TFEB on autophagic accumulation – the major secondary abnormality in PD skeletal muscle (Raben et al, 2007a,b, 2012).”
BackgroundSelf-citationTiels, P., Baranova, E., Piens, K., Visscher, C. D., Pynaert, G., Nerinckx, W., Stout, J., Fudalej, F., Hulpiau, P., Tännler, S., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2427 · Cited by 109 · cited 1×
“…the current therapy, such as the development of ‘‘second generation’’ recombinant enzymes with enhanced targeting properties (Maga et al, 2012; Tiels et al, 2012; Zhu et al, 2009), pharmacological chaperones that assist the folding of the mutant enzyme (Okumiya et al, 2007; Parenti et al,…”
BackgroundPharmacological Enhancement of α-Glucosidase by the Allosteric Chaperone N-acetylcysteine
Porto, C., Ferrara, M. C., Meli, M., Acampora, E., Avolio, V., Rosa, M., Cobucci-Ponzano, B., Colombo, G., Moracci, M., Andria, G., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.152 · Cited by 109 · cited 1×
“…properties (Maga et al, 2012; Tiels et al, 2012; Zhu et al, 2009), pharmacological chaperones that assist the folding of the mutant enzyme (Okumiya et al, 2007; Parenti et al, 2007) or increase the stability of the recombinant enzyme (Porto et al, 2009, 2012), and gene therapy (Byrne et al, 2011).”
BackgroundSelf-citationMaga, J. A., Zhou, J., Kambampati, R., Peng, S. S., Wang, X., Bohnsack, R. N., Thomm, A. M., Golata, S., Tom, P., Dahms, N. M., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.438663 · Cited by 108
Okumiya, T., Kroos, M. A., de Vliet, L. V., Takeuchi, H., van der Ploeg, A. T., & Reuser, A. J. J. (2006) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.09.010 · Cited by 106 · cited 1×
“…targeting properties (Maga et al, 2012; Tiels et al, 2012; Zhu et al, 2009), pharmacological chaperones that assist the folding of the mutant enzyme (Okumiya et al, 2007; Parenti et al, 2007) or increase the stability of the recombinant enzyme (Porto et al, 2009, 2012), and gene therapy (Byrne…”
BackgroundRole of autophagy in the pathogenesis of Pompe disease.
Raben, N., Roberts, A., & Plötz, P. H. (2007) · Europe PMC (PubMed Central) · Cited by 104
Self-citationDNA Transfection of Mammalian Skeletal Muscles using In Vivo Electroporation
DiFranco, M., Quinonez, M., Capote, J., & Vergara, J. (2009) · Journal of Visualized Experiments · doi:10.3791/1520 · Cited by 101 · cited 1×
“Electric pulse-mediated gene transfer into FDB muscle was performed as described (DiFranco et al, 2009).”
Funk, B. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.2.424 · Cited by 98 · cited 1×
“…response to the recombinant enzyme in cross-reactive immunologic material (CRIM)-negative patients and the presence of large areas of autophagic build-up alongside expanded lysosomes (Banugaria et al, 2011; Funk et al, 1992; Kishnani et al, 2010; Koeberl et al, 2012; Raben et al, 2002, 2010, 2012).”
Chapter 21 Monitoring Autophagy in Lysosomal Storage Disorders
Raben, N., Shea, L., Hill, V., & Plotz, P. (2009) · Methods in Enzymology · doi:10.1016/s0076-6879(08)04021-4 · Cited by 97 · cited 1×
“Immunostaining with LAMP1, LC3 or Flag antibodies was done using M.O.M. kit (Vector Laboratories, Burlingame, CA) as previously described (Raben et al, 2009).”
MethodSelf-citationByrne, B. J., Falk, D. J., Pacak, C. A., Nayak, S., Herzog, R. W., Elder, M. E., Collins, S. W., Conlon, T. J., Clement, N., Cleaver, B. D., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr174 · Cited by 91 · cited 1×
“…properties (Maga et al, 2012; Tiels et al, 2012; Zhu et al, 2009), pharmacological chaperones that assist the folding of the mutant enzyme (Okumiya et al, 2007; Parenti et al, 2007) or increase the stability of the recombinant enzyme (Porto et al, 2009, 2012), and gene therapy (Byrne et al, 2011).”
Therapeutic Approaches in Glycogen Storage Disease Type II/Pompe Disease
Schoser, B. G. H., Hill, V. K., & Raben, N. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.08.009 · Cited by 87 · cited 1×
“…1 and Lumizyme 1 , Genzyme Corporation, Framingham, MA), many patients experience limited clinical benefit or show signs of disease progression (Angelini & Semplicini, 2012; Kishnani et al, 2007; Schoser et al, 2008; Strothotte et al, 2010; Van den Hout et al, 2004; Van der Ploeg et al, 2010).”
Self-citationRaben, N., Jatkar, T., Lee, A., Lu, N., Dwivedi, S., Nagaraju, K., & Plötz, P. H. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0716 · Cited by 67 · cited 1×
“…response to the recombinant enzyme in cross-reactive immunologic material (CRIM)-negative patients and the presence of large areas of autophagic build-up alongside expanded lysosomes (Banugaria et al, 2011; Funk et al, 1992; Kishnani et al, 2010; Koeberl et al, 2012; Raben et al, 2002, 2010, 2012).”
BackgroundSelf-citation“Fluorescent glycogen” formation with sensibility for in vivo and in vitro detection
Louzao, M. C., Espiña, B., Vieytes, M. R., Vega, F. V., Rubiolo, J. A., Baba, O., Terashima, T., & Botana, L. M. (2007) · Glycoconjugate Journal · doi:10.1007/s10719-007-9075-7 · Cited by 59 · cited 1×
“…detection, LDH measurements, in situ detection of apoptotic cells, surface LAMP1 analysis, and acid phosphatase assay Lysosomal glycogen in live cells was detected by the incorporation of 2-NBDG, a D -glucose fluorescent derivative (2-deoxyglucose), into glycogen as described (Louzao et al, 2008).”
Raben, N., Jatkar, T., LEE, A., et al. (2002) · Molecular Therapy · doi:10.1016/s1525-0016(02)90716-1 · Cited by 59
Self-citationβ2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease
Koeberl, D. D., Li, S., Dai, J., Thurberg, B. L., Bali, D. S., & Kishnani, P. S. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.11.005 · Cited by 51 · cited 1×
“…response to the recombinant enzyme in cross-reactive immunologic material (CRIM)-negative patients and the presence of large areas of autophagic build-up alongside expanded lysosomes (Banugaria et al, 2011; Funk et al, 1992; Kishnani et al, 2010; Koeberl et al, 2012; Raben et al, 2002, 2010, 2012).”
BackgroundEnzyme Replacement Therapy for Pompe Disease
Angelini, C. I., & Semplicini, C. (2011) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-011-0236-5 · Cited by 48 · cited 1×
“…1 and Lumizyme 1 , Genzyme Corporation, Framingham, MA), many patients experience limited clinical benefit or show signs of disease progression (Angelini & Semplicini, 2012; Kishnani et al, 2007; Schoser et al, 2008; Strothotte et al, 2010; Van den Hout et al, 2004; Van der Ploeg et al, 2010).”
Exocytosis of storage material in a lysosomal disorder
Klein, D., Büssow, H., Fewou, S. N., & Gieselmann, V. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.12.054 · Cited by 43 · cited 1×
“Interestingly, lysosomal exocytosis has been implicated as a mechanism of cellular clearance in cell models of several LSDs, such as metachromatic leukodystrophy and mucolipidosis type I (Klein et al, 2005; Yogalingam et al, 2008).”
Murine muscle cell models for Pompe disease and their use in studying therapeutic approaches
Takikita, S., Myerowitz, R., Zaal, K., Raben, N., & Plotz, P. H. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2008.12.012 · Cited by 42 · cited 1×
“…cells from human induced pluripotent stem (iPS) cells (Huang et al, 2011), muscle cells from reprogrammed murine iPS cells (Kawagoe et al, 2011), and murine muscle cells transduced by viral constructs containing immortalizing genes (Douillard-Guilloux et al, 2009; Takikita et al, 2009).”
Self-citationKawagoe, S., Higuchi, T., Meng, X., Shimada, Y., Shimizu, H., Hirayama, R., Fukuda, T., Chang, H. C., Nakahata, T., Fukada, S., et al. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.05.020 · Cited by 33 · cited 1×
“…of cardiomyocyte-like cells from human induced pluripotent stem (iPS) cells (Huang et al, 2011), muscle cells from reprogrammed murine iPS cells (Kawagoe et al, 2011), and murine muscle cells transduced by viral constructs containing immortalizing genes (Douillard-Guilloux et al, 2009; Takikita…”
Mouly, V., Edom‐Vovard, F., Decary, S., Vicart, P., Barbet, P., & Butler-Browne, G. S. (1996) · Experimental Cell Research · doi:10.1006/excr.1996.0176 · Cited by 28 · cited 1×
“…muscle cell lines have several advantages: they are highly myogenic, derived from individual clones and, most importantly, they maintain the capacity to differentiate when the immortalizing gene, shown to perturb myogenic program (Douillard-Guilloux et al, 2009; Mouly et al, 1996), is inactivated.”
Recent Developments in Therapeutic Approaches for Lysosomal Storage Diseases
Urbanelli, L., Magini, A., Polchi, A., Polidoro, M., & Emiliani, C. (2010) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488911794079127 · Cited by 23 · cited 1×
“Unfortunately, in many of these diseases the target tissues are not easily accessible to the replacement enzymes (Lachmann, 2011; Urbanelli et al, 2011).”
Douillard‐Guilloux, G., Mouly, V., Caillaud, C., & Richard, E. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.08.006 · Cited by 12 · cited 2×
“…muscle cell lines have several advantages: they are highly myogenic, derived from individual clones and, most importantly, they maintain the capacity to differentiate when the immortalizing gene, shown to perturb myogenic program (Douillard-Guilloux et al, 2009; Mouly et al, 1996), is inactivated.”
Background
Cited by
The role of autophagy in neurodegenerative disease
Nixon, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3232 · Cited by 2,059
Signals from the lysosome: a control centre for cellular clearance and energy metabolism
Settembre, C., Fraldi, A., Medina, D. L., & Ballabio, A. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3565 · Cited by 1,697
Self-citationAutophagy in major human diseases
Klionsky, D. J., Petroni, G., Amaravadi, R. K., Baehrecke, E. H., Ballabio, A., Boya, P., Bravo‐San Pedro, J. M., Cadwell, K., Cecconi, F., Choi, A. M. K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108863 · Cited by 1,585
Self-citationLysosomes as dynamic regulators of cell and organismal homeostasis
Ballabio, A., & Bonifacino, J. S. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0185-4 · Cited by 1,469
Self-citationXu, H., & Ren, D. (2015) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021014-071649 · Cited by 1,034
“Strikingly, the beneficial effects of TFEB on various LSDs depend on TRPML1 and lysosomal exocytosis (49, 133).”
Background
Metadata
- Authors
- Spampanato, C., Feeney, E., Li, L., Cardone, M., Lim, J., Annunziata, F., Zare, H., Polishchuk, R., Puertollano, R., Parenti, G., Ballabio, A., & Raben, N.
- Affiliations
- Baylor College of Medicine (US)
- National Institutes of Health (US)
- Telethon Institute Of Genetics And Medicine (IT)
- Federico II University Hospital (IT)
- Corresponding author
- Ballabio, Andrea
- Raben, Nina
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2013-04-18
- Volume
- 5
- Issue
- 5
- Pages
- 691-706
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC3662313
- OpenAlex
- W2113698463
- Cited by
- 341
- References
- 68
- Citations by year
- 2026: 9 · 2025: 20 · 2024: 23 · 2023: 20 · 2022: 24 · 2021: 33 · 2020: 29 · 2019: 37 · 2018: 22 · 2017: 22 · 2016: 35 · 2015: 29 · 2014: 28 · 2013: 10
- FWCI
- 23.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- public-domain
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- March of Dimes Foundation
- Beyond Batten Disease Foundation
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke (R01NS078072)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- FP7 Ideas: European Research Council (250154)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- TFEB, Pompe disease, lysosomal storage disease, autophagy, lysosomal exocytosis, acid alpha-glucosidase deficiency, skeletal muscle, therapeutic target, lysosomal dysfunction
- MeSH terms
- Adenoviridae, alpha-Glucosidases, Animals, Autophagy, Cells, Cultured, Disease Models, Animal, Exocytosis, Genetic Vectors, Glycogen, Glycogen Storage Disease Type II, Lysosomes, Mice, Knockout, Muscle, Skeletal, Mice, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.